Hostname: page-component-8448b6f56d-mp689 Total loading time: 0 Render date: 2024-04-24T03:27:56.770Z Has data issue: false hasContentIssue false

A.03 Durable clinical and MRI efficacy of alemtuzumab over 6 years in CARE-MS II patients with RRMS who relapsed between Courses 1 and 2

Published online by Cambridge University Press:  27 June 2018

MS Freedman
Affiliation:
(Ottawa)
S Broadley
Affiliation:
(Gold Coast)
A Chinea
Affiliation:
(San Juan)
G Izquierdo
Affiliation:
(Seville)
J Lycke
Affiliation:
(Gothenburg)
BA Singer
Affiliation:
(St Louis)
B Steingo
Affiliation:
(Fort Lauderdale)
H Wiendl
Affiliation:
(Münster)
S Wray
Affiliation:
(Knoxville)
M Melanson
Affiliation:
(Cambridge)
K Thangavelu
Affiliation:
(Cambridge)
A Boster
Affiliation:
(Columbus)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: In RRMS patients with inadequate response to prior therapy, 2 alemtuzumab courses (12 mg/day; baseline: 5 days; 12 months later: 3 days) significantly improved outcomes over 2 years (y) versus SC IFNB-1a (CARE-MS II [NCT00548405]), with durable efficacy over a 4-y extension (NCT00930553). We present 6-y efficacy (2-y core study plus 4-y extension) in patients with relapse (relapsers) between Courses (C) 1 and 2. Methods: Annualized relapse rate (ARR); 6-month confirmed disability worsening (CDW); MRI disease activity (Gd-enhancing lesions; new/enlarging T2 hyperintense lesions); brain volume loss (BVL; derived by relative change in brain parenchymal fraction). Results: 105/435 (24%) patients relapsed between C1 and C2; 33% (relapsers) versus 55% without relapse (non-relapsers) received neither alemtuzumab retreatment nor another disease-modifying therapy through Y6. ARR (Y1: 1.2) declined post-C2 (0.5), remaining low through Y6 (0.2 [0.1, non-relapsers]; 10/105 [10%] relapsed). Through Y6, patients remained CDW-free (60% [relapsers]; 75% [non-relapsers]), Gd-enhancing lesion-free (94% [relapsers]; 90% [non-relapsers]), new/enlarging T2 hyperintense lesion-free (68% [relapsers]; 69% [non-relapsers]), and MRI disease activity-free (68% [relapsers]; 69% [non-relapsers]). Alemtuzumab slowed median percent yearly BVL (Y6: -0.13% [relapsers]; -0.10% [non-relapsers]). Conclusions: Patients relapsing between C1 and C2 improved post-C2 through Y6. These findings support administering 2 alemtuzumab courses to achieve optimal and durable benefit.

Type
PLATFORM PRESENTATIONS
Copyright
© The Canadian Journal of Neurological Sciences Inc. 2018